Cormark set a C$7.50 price target on Vitalhub (TSE:VHI - Free Report) in a research report released on Monday, BayStreet.CA reports. The brokerage currently has a buy rating on the stock.
VHI has been the subject of several other reports. Canaccord Genuity Group lifted their target price on shares of Vitalhub from C$5.25 to C$5.50 and gave the stock a buy rating in a research note on Tuesday, February 6th. Eight Capital boosted their price objective on shares of Vitalhub from C$5.00 to C$6.25 and gave the company a buy rating in a research note on Tuesday, February 6th.
Check Out Our Latest Stock Analysis on VHI
Vitalhub Price Performance
Shares of VHI stock traded up C$0.18 during trading hours on Monday, reaching C$6.00. 140,089 shares of the company's stock were exchanged, compared to its average volume of 164,863. Vitalhub has a 1 year low of C$2.35 and a 1 year high of C$6.86. The company's 50 day moving average is C$5.97 and its two-hundred day moving average is C$4.50. The company has a market cap of C$262.26 million, a P/E ratio of 60.40, a price-to-earnings-growth ratio of 0.42 and a beta of 1.21.
Vitalhub (TSE:VHI - Get Free Report) last released its quarterly earnings results on Thursday, March 21st. The company reported C$0.03 earnings per share for the quarter, missing analysts' consensus estimates of C$0.04 by C($0.01). The firm had revenue of C$13.60 million during the quarter, compared to analyst estimates of C$13.68 million. Vitalhub had a return on equity of 5.78% and a net margin of 8.66%. As a group, analysts predict that Vitalhub will post 0.1501823 EPS for the current fiscal year.
Vitalhub Company Profile
(
Get Free Report)
Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
See Also
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
